Monday, August 15, 2022 12:12:46 AM
Same science but Kite had nothing to do with the checkpoint NR2F6.
Actually neither does Eli Lilly. They gained access thru the NIH program but Regen pulled out. They were gaining nothing from it.
Regen is the only company I know of that seems to have corralled a checkpoint (NR2F6) with patents.
Nothing else actually matters now, car T is it and they've just made a big discovery.
Good Luck!!!
Actually neither does Eli Lilly. They gained access thru the NIH program but Regen pulled out. They were gaining nothing from it.
Regen is the only company I know of that seems to have corralled a checkpoint (NR2F6) with patents.
Nothing else actually matters now, car T is it and they've just made a big discovery.
Good Luck!!!
Recent RGBP News
- Regen BioPharma Update on Orphan Drug Application for HemaXellerate Will Be Presented At Emerging Growth Conference on September 24, 2025 • GlobeNewswire Inc. • 09/23/2025 12:00:00 PM
- Regen BioPharma Prepares Response For FDA Regarding Its Orphan Drug Application for HemaXellerate • GlobeNewswire Inc. • 09/16/2025 12:00:00 PM
